vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
May 24, 2023 09:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for...
vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update
May 11, 2023 16:15 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for...
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
March 06, 2023 17:56 ET
|
vTv Therapeutics Inc.
Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetesBiotech industry and Wall Street veteran Steven Tuch appointed...
Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
February 01, 2023 17:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
December 13, 2022 08:15 ET
|
vTv Therapeutics Inc.
Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the...
vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
November 10, 2022 17:25 ET
|
vTv Therapeutics Inc.
Company on-track to initiate Phase 3 clinical trials of TTP399 in the first quarter of 2023 Industry veteran Paul Sekhri joins the Company as President, Chief Executive Officer, and member of the...
vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update
August 15, 2022 18:43 ET
|
vTv Therapeutics Inc.
Paul Sekhri appointed as President, Chief Executive Officer and Board member. Entered into agreements with CinRx Pharma and a subsidiary to purchase $10 million in stock and to leverage CinRx’s...
vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer
July 27, 2022 07:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics Announces Investment by CinRx Pharma
July 25, 2022 07:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a...
vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
June 04, 2022 11:00 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., June 04, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for...